|Bid||0.00 x 900|
|Ask||0.00 x 3200|
|Day's Range||1.14 - 1.21|
|52 Week Range||0.91 - 2.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie ...
Organovo Holdings, Inc. (ONVO) (“Organovo” or the “Company”) announced the grant of inducement awards on August 14, 2018 to Dr. Steven G. Hughes, its new chief medical officer. The inducement awards were approved by the compensation committee of the Company’s board of directors and issued as a material inducement to Dr. Hughes agreeing to join the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
Pre-Investigational New Drug meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency expected to commence IND-enabling studies in second half of calendar ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern ...
Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that Steven G. Hughes has been named Chief Medical Officer. Dr. Hughes is an industry veteran who brings significant experience directing clinical development and medical affairs teams at leading biopharma companies. Dr. Hughes most recently served as the Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of 25 drugs across 10 therapeutic areas including cardiovascular, metabolic, oncology and rare diseases. Previously, he held positions as Global Medical Lead, Oncology Clinical Development and Medical Director, UK & Ireland at Biogen Idec. Dr. Hughes also held numerous senior clinical development, medical affairs and leadership positions of increasing responsibility at CSL Behring and Sanofi. Dr. Hughes is board certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA with distinction from Imperial College Business School.
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
SAN DIEGO, July 19, 2018-- Organovo Holdings, Inc. will host a conference call on Thursday, August 9, 2018 at 5:00 p.m. Eastern Time to discuss the Company's fiscal first-quarter 2019 operating and financial ...
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
Late-Breaking Poster Presented at The International Liver Congress SAN DIEGO and KALAMAZOO, Mich. , April 12, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it presented a late-breaking ...
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 8, 2018 at 5:00 PM Eastern ...